Search

Your search keyword '"Hajjaji, Nawale"' showing total 37 results
Start Over Author "Hajjaji, Nawale"
37 results on '"Hajjaji, Nawale"'

3. Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

Author

de Moura, Alexandre, Vuagnat, Perrine, Renouf, Benjamin, Pierga, Jean-Yves, Loirat, Delphine, Vaflard, Pauline, Lafayolle de la Bruyère, Charline, Chaumard-Billotey, Natacha, Hajjaji, Nawale, Ladoire, Sylvain, Dabakuyo, Sandrine, Patsouris, Anne, Frenel, Jean Sébastien, Nicolai, Vincent, Alexandre, Marie, Dohollou, Nadine, Grenier, Julien, Bourien, Heloïse, and Bidard, François-Clément

Published
2023
Full Text
View/download PDF

7. Genomics to select treatment for patients with metastatic breast cancer

Author

Andre, Fabrice, Filleron, Thomas, Kamal, Maud, Mosele, Fernanda, Arnedos, Monica, Dalenc, Florence, Sablin, Marie-Paule, Campone, Mario, Bonnefoi, Hervé, Lefeuvre-Plesse, Claudia, Jacot, William, Coussy, Florence, Ferrero, Jean-Marc, Emile, George, Mouret-Reynier, Marie-Ange, Thery, Jean-Christophe, Isambert, Nicolas, Mege, Alice, Barthelemy, Philippe, You, Benoit, Hajjaji, Nawale, Lacroix, Ludovic, Rouleau, Etienne, Tran-Dien, Alicia, Boyault, Sandrine, Attignon, Valery, Gestraud, Pierre, Servant, Nicolas, Le Tourneau, Christophe, Cherif, Linda Larbi, Soubeyran, Isabelle, Montemurro, Filippo, Morel, Alain, Lusque, Amelie, Jimenez, Marta, Jacquet, Alexandra, Gonçalves, Anthony, Bachelot, Thomas, and Bieche, Ivan

Published
2022
Full Text
View/download PDF

8. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France

Author

Petit, Thierry, primary, Hajjaji, Nawale, additional, Antoine, Eric‐Charles, additional, Benderra, Marc‐Antoine, additional, Gozy, Michel, additional, Foa, Cyril, additional, Mouysset, Jean‐Loup, additional, Grenier, Julien, additional, Mousseau, Mireille, additional, Mailliez, Audrey, additional, Saghatchian, Mahasti, additional, Lachaier, Emma, additional, Desmoulins, Isabelle, additional, Hennequin, Audrey, additional, Maes, Patricia, additional, Loirat, Delphine, additional, Ricci, Francesco, additional, Diéras, Véronique, additional, Berton, Dominique, additional, Tiong, Florence Lai, additional, Teixeira, Luis, additional, Dohollou, Nadine, additional, Lévy, Christelle, additional, Bachelot, Thomas, additional, and Pierga, Jean‐Yves, additional

Published
2024
Full Text
View/download PDF

9. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups

Author

Pasquier, David, primary, Bidaut, Luc, additional, Oprea-Lager, Daniela Elena, additional, deSouza, Nandita M, additional, Krug, David, additional, Collette, Laurence, additional, Kunz, Wolfgang, additional, Belkacemi, Yazid, additional, Bau, Maria Grazia, additional, Caramella, Caroline, additional, De Geus-Oei, Lioe-Fee, additional, De Caluwé, Alex, additional, Deroose, Christophe, additional, Gheysens, Olivier, additional, Herrmann, Ken, additional, Kindts, Isabelle, additional, Kontos, Michalis, additional, Kümmel, Sherko, additional, Linderholm, Barbro, additional, Lopci, Egesta, additional, Meattini, Icro, additional, Smeets, Ann, additional, Kaidar-Person, Orit, additional, Poortmans, Philip, additional, Tsoutsou, Pelagia, additional, Hajjaji, Nawale, additional, Russell, Nicola, additional, Senkus, Elżbieta, additional, Talbot, Jean-Noël, additional, Umutlu, Lale, additional, Vandecaveye, Vincent, additional, Verhoeff, Joost J C, additional, van Oordt, Willemien Menke-van der Houven, additional, Zacho, Helle D, additional, Cardoso, Fatima, additional, Fournier, Laure, additional, Van Duijnhoven, Frederieke, additional, and Lecouvet, Frédéric E, additional

Published
2023
Full Text
View/download PDF

10. Fallopian tube lesions as potential precursors of early ovarian cancer: A comprehensive proteomic analysis

Author

Salzet, Michel, primary, Wisztorski, Maxence, additional, Aboulouard, Soulaimane, additional, Roussel, Lucas, additional, Duhamel, Marie, additional, saudemont, Philippe, additional, Tristan, Cardon, additional, Narducci, Fabrice, additional, Robin, Yves-Marie, additional, Lemaire, Anne-Sophie, additional, Bertin, delphine, additional, Hajjaji, Nawale, additional, Kobaissy, Firas, additional, Fournier, Isabelle, additional, and Leblanc, Eric, additional

Published
2023
Full Text
View/download PDF

18. Identifying Diagnostic Markers for Early the Preneoplastic Transformation of Fimbria Lesions at the Origin of Ovarian Cancer in BRCA Mutated Patients

Author

Wisztorski, Maxence, primary, Aboulouard, Soulaimane, additional, Roussel, Lucas, additional, Duhamel, Marie, additional, Saudemont, Philippe, additional, Cardon, Tristan, additional, Narducci, Fabrice, additional, Robin, Yves-Marie, additional, Lemaire, Anne-Sophie, additional, Bertin, Delphine, additional, Hajjaji, Nawale, additional, Kobeissy, Firas, additional, Leblanc, Eric, additional, Fournier, Isabelle, additional, and Salzet, Michel, additional

Published
2022
Full Text
View/download PDF

19. Surfaceome proteomic of glioblastoma revealed potential targets for immunotherapy

Author

Rose, Melanie, Cardon, Tristan, Aboulouard, Soulaimane, Hajjaji, Nawale, Kobeissy, Firas, Duhamel, Marie, Fournier, Isabelle, Salzet, Michel, INSERM, Université de Lille, Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192, Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 [PRISM], American University of Beirut [Beyrouth] [AUB], Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and American University of Beirut [Beyrouth] (AUB)

Subjects
Proteomics, mutated proteins, Clinical Trials as Topic, clinical trials, Brain Neoplasms, Protein Conformation, [SDV]Life Sciences [q-bio], Immunology, glioblastoma, surface proteins, Brain, Membrane Proteins, Antineoplastic Agents, drugs, Neoplasm Proteins, Cell Line, Tumor, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, immune therapy, Drug Discovery, surfaceome proteomic, Humans, Immunotherapy, Molecular Targeted Therapy, Original Research
Abstract

International audience; Glioblastoma (GBM) is the most common and devastating malignant brain tumor in adults. The mortality rate is very high despite different treatments. New therapeutic targets are therefore highly needed. Cell-surface proteins represent attractive targets due to their accessibility, their involvement in essential signaling pathways, and their dysregulated expression in cancer. Moreover, they are potential targets for CAR-based immunotherapy or mRNA vaccine strategies. In this context, we investigated the GBM-associated surfaceome by comparing it to astrocytes cell line surfaceome to identify new specific targets for GBM. For this purpose, biotinylation of cell surface proteins has been carried out in GBM and astrocytes cell lines. Biotinylated proteins were purified on streptavidin beads and analyzed by shotgun proteomics. Cell surface proteins were identified with Cell Surface Proteins Atlas (CSPA) and Gene Ontology enrichment. Among all the surface proteins identified in the different cell lines we have confirmed the expression of 66 of these in patient's glioblastoma using spatial proteomic guided by MALDI-mass spectrometry. Moreover, 87 surface proteins overexpressed or exclusive in GBM cell lines have been identified. Among these, we found 11 specific potential targets for GBM including 5 mutated proteins such as RELL1, CYBA, EGFR, and MHC I proteins. Matching with drugs and clinical trials databases revealed that 7 proteins were druggable and under evaluation, 3 proteins have no known drug interaction yet and none of them are the mutated form of the identified proteins. Taken together, we discovered potential targets for immune therapy strategies in GBM.

Published
2021
Full Text
View/download PDF

23. Protocol for generating a co-culture of macrophages with breast cancer tumoroids

Author

Raffo-Romero, Antonella, Ziane-Chaouche, Lydia, Hajjaji, Nawale, Salzet, Michel, and Duhamel, Marie

Abstract

Cancer progression and treatment outcomes are heavily influenced by the tumor microenvironment (TME), especially through immune cell interactions. Here, we present a protocol for generating co-cultures of tumoroids with macrophages, either semi-liquid or Matrigel-embedded. We describe steps for macrophage preparation, co-culture establishment, and medium adjustments to support cell viability and function. While optimized for breast cancer models, this protocol can be adapted to other tumor types with appropriate medium adjustments.

Published
2025
Full Text
View/download PDF

35. Determinants of DHA incorporation into tumor tissue during dietary DHA supplementation

Author

Philippe Bougnoux, Nawale Hajjaji, Valérie Schubnel, Hajjaji, Nawale, Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Zootechnie, and École de Médecine

Subjects
MESH: Carcinoma, genetic structures, medicine.medical_treatment, MESH: Dietary Supplements, MESH: Rats, Sprague-Dawley, Biochemistry, Rats, Sprague-Dawley, 0302 clinical medicine, Tissue Distribution, MESH: Animals, Phospholipids, 0303 health sciences, Mammary tumor, Chemistry, Fatty Acids, food and beverages, Methylnitrosourea, tumor phospholipids, 3. Good health, dietary DHA supplementation, MESH: Fatty Acids, DHA incorporation, MESH: Docosahexaenoic Acids, Docosahexaenoic acid, MESH: Dietary Fats, 030220 oncology & carcinogenesis, Female, lipids (amino acids, peptides, and proteins), Fatty acid composition, Lipidology, MESH: Triglycerides, medicine.medical_specialty, Docosahexaenoic Acids, MESH: Rats, Clinical chemistry, MESH: Mammary Neoplasms, Experimental, plasma phospholipids, [SDV.CAN]Life Sciences [q-bio]/Cancer, tumor triacylglycerol, Article, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Palm oil, medicine, Animals, MESH: Methylnitrosourea, mammary tumors, MESH: Tissue Distribution, Triglycerides, 030304 developmental biology, MESH: Phospholipids, Chemotherapy, Organic Chemistry, Carcinoma, Mammary Neoplasms, Experimental, Cell Biology, Tumor tissue, Dietary Fats, Rats, Endocrinology, Dietary Supplements, MESH: Female
Abstract

International audience; Docosahexaenoic acid (DHA), upon incorporation into tumor tissue, has the potential to sensitize tumors to the effects of chemotherapy or radiation therapy. Although DHA has usually been supplied to tumor tissue in the diet, appropriate dietary conditions required to obtain optimal tumor levels have not been established. Hence, we studied mammary tumor tissue responses in rats fed various durations and doses of DHA. Rats fed a palm oil enriched diet (diet 0) were switched to diets providing either 0.8 g DHA/day (diet 1) or 1.5 g DHA/day (diet 2). Tumor tissue fatty acid composition was analysed at baseline (diet 0), at weeks 1, 4 and 9 during diet 1 and at week 4 during diet 2. Dietary DHA supplementation differentially increased DHA within phospholipids (PL) and triacylglycerol (TAG) fractions in tumors. DHA level equilibrated between 2 and 4 weeks in PL while DHA increase was more progressive in TAG and did not reach a steady state. A higher dose of DHA further increased DHA content in tumor PL and TAG (P = 0.018 and P < 0.001, respectively). DHA concentration in plasma PL was positively correlated with DHA in tumor PL (r = 0.72; P = 0.0003) and TAG (r = 0.64; P = 0.003). We conclude that dietary DHA supplementation enhances tumor content of DHA in a time- and dose-dependent manner, and that the DHA level in plasma PL could be used as a proxy for tumor DHA. These findings have implications for dietary DHA supplementations in cancer patients.

Published
2011
Full Text
View/download PDF

36. Protocol for generating a co-culture of macrophages with breast cancer tumoroids.

Author

Raffo-Romero A, Ziane-Chaouche L, Hajjaji N, Salzet M, and Duhamel M

Abstract

Cancer progression and treatment outcomes are heavily influenced by the tumor microenvironment (TME), especially through immune cell interactions. Here, we present a protocol for generating co-cultures of tumoroids with macrophages, either semi-liquid or Matrigel-embedded. We describe steps for macrophage preparation, co-culture establishment, and medium adjustments to support cell viability and function. While optimized for breast cancer models, this protocol can be adapted to other tumor types with appropriate medium adjustments. For complete details on the use and execution of this protocol, please refer to Raffo-Romero et al. 1 ., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

37. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy.

Author

Rose M, Cardon T, Aboulouard S, Hajjaji N, Kobeissy F, Duhamel M, Fournier I, and Salzet M

Subjects
Antineoplastic Agents therapeutic use, Brain metabolism, Brain Neoplasms genetics, Brain Neoplasms therapy, Cell Line, Tumor, Clinical Trials as Topic, Drug Discovery, Glioblastoma genetics, Glioblastoma therapy, Humans, Membrane Proteins antagonists & inhibitors, Membrane Proteins chemistry, Membrane Proteins genetics, Molecular Targeted Therapy, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins chemistry, Neoplasm Proteins genetics, Protein Conformation, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Antineoplastic Agents pharmacology, Brain Neoplasms metabolism, Glioblastoma metabolism, Immunotherapy methods, Membrane Proteins metabolism, Neoplasm Proteins metabolism, Proteomics methods
Abstract

Glioblastoma (GBM) is the most common and devastating malignant brain tumor in adults. The mortality rate is very high despite different treatments. New therapeutic targets are therefore highly needed. Cell-surface proteins represent attractive targets due to their accessibility, their involvement in essential signaling pathways, and their dysregulated expression in cancer. Moreover, they are potential targets for CAR-based immunotherapy or mRNA vaccine strategies. In this context, we investigated the GBM-associated surfaceome by comparing it to astrocytes cell line surfaceome to identify new specific targets for GBM. For this purpose, biotinylation of cell surface proteins has been carried out in GBM and astrocytes cell lines. Biotinylated proteins were purified on streptavidin beads and analyzed by shotgun proteomics. Cell surface proteins were identified with Cell Surface Proteins Atlas (CSPA) and Gene Ontology enrichment. Among all the surface proteins identified in the different cell lines we have confirmed the expression of 66 of these in patient's glioblastoma using spatial proteomic guided by MALDI-mass spectrometry. Moreover, 87 surface proteins overexpressed or exclusive in GBM cell lines have been identified. Among these, we found 11 specific potential targets for GBM including 5 mutated proteins such as RELL1, CYBA, EGFR, and MHC I proteins. Matching with drugs and clinical trials databases revealed that 7 proteins were druggable and under evaluation, 3 proteins have no known drug interaction yet and none of them are the mutated form of the identified proteins. Taken together, we discovered potential targets for immune therapy strategies in GBM., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Rose, Cardon, Aboulouard, Hajjaji, Kobeissy, Duhamel, Fournier and Salzet.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results